Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 3 2Phase 1/2 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 12INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1HER2-negative Breast Cancer 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × pamiparib × Clear all
NCT03427814 2024-10-26

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

BeiGene

Phase 2 Completed
136 enrolled 16 charts
Gastrointestinal

Stomach Neoplasms

NCT03575065 2024-10-26

Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

BeiGene

Phase 2 Completed
88 enrolled 17 charts
Breast

HER2-negative Breast Cancer

NCT03712930 2021-11-17

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

BeiGene

Phase 2 Terminated
13 enrolled 11 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡